[144] Ginkgo Bioworks Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. (DNA) filing a Form 144 notifies a proposed sale of 2,200 Class A shares held by the reporting person through Fidelity Brokerage Services. The shares were acquired on 10/18/2022 via restricted stock vesting as compensation. The filing lists an aggregate market value of $33,462.00 for the 2,200 shares and names the planned sale date as 10/08/2025 on the NYSE. The record also shows three prior Class A sales in the past three months totaling 6,600 shares with gross proceeds of $24,596.00, $31,020.00, and $23,716.00 on 07/09/2025, 08/06/2025, and 09/10/2025, respectively. The filer represents no undisclosed material adverse information and certifies the accuracy of the notice.

Insights

Equity Compensation Analyst

Executive equity vesting led to routine secondary-market sales.

The reporting person acquired 2,200 Class A shares on 10/18/2022 through restricted stock vesting, which is a common form of compensation for employees and executives. The planned sale on 10/08/2025 and prior three monthly sales indicate conversion of vested holdings into cash.

Primary dependency is trading-window and Rule 144 compliance; these sales are documented under Form 144 and list a broker and exchange, suggesting routine liquidity activity over a multi-month period. Monitor any sudden increase in volume relative to public float and future Form 4/Form 144 filings for continuation within the next 30-90 days.

Market Impact Specialist

Individual sales are small relative to company float and likely immaterial to share price.

The filing reports 2,200 shares to be sold against 47,089,598 shares outstanding, representing a de minimis fraction of the float. Prior three sales totaling 6,600 shares further suggest modest insider liquidity rather than a significant exit.

Key near-term item to observe is whether future insider filings show materially larger sales; absent that, these transactions are unlikely to be market-moving within the next 30-90 days.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2200	33462.00	47089598	10/08/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	10/18/2022	Restricted Stock Vesting	Issuer			2200	10/18/2022	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Austin Che 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	07/09/2025	2200	24596.00
Austin Che 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	08/06/2025	2200	31020.00
Austin Che 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	09/10/2025	2200	23716.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for Ginkgo Bioworks (DNA) disclose?

The notice reports a proposed sale of 2,200 Class A shares acquired on 10/18/2022 by restricted stock vesting, with an aggregate market value of $33,462.00 and a planned sale date of 10/08/2025 on the NYSE.

Who is the seller named in the Form 144 for DNA?

The filing lists the reporting person as Austin Che with an address in Boston, and identifies Fidelity Brokerage Services LLC as the broker.

Have there been recent sales by this person before this filing?

Yes; the filing lists three prior Class A sales in the past three months: 07/09/2025 ($24,596.00), 08/06/2025 ($31,020.00), and 09/10/2025 ($23,716.00), each for 2,200 shares.

How material is the proposed sale relative to Ginkgo Bioworks' shares outstanding?

The proposed 2,200 shares compare to 47,089,598 shares outstanding, representing a very small fraction of the total share count.

Does the filer assert any undisclosed material information?

By signing, the filer represents that they do not know any material adverse information about the issuer that has not been publicly disclosed.